Faster, More Efficient Protein Labeling Developed By Chemists

North Carolina State University researchers have created specially engineered mammalian cells to provide a new “chemical handle” which will enable researchers to label proteins of interest more efficiently, without disrupting the normal function of the proteins themselves or the cells in which they are found…

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B.

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI anthrax rPA subunit protein vaccine, known as SGX204.

Actavis, Scil Proteins sign Reteplase supply agreement

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world’s leading generic pharmaceutical companies, for the future manufacturing of Reteplase.

Protein Test Found to Boost NSCLC Survival, Costs (CME/CE)

SAN DIEGO (MedPage Today) — Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer, computer modeling suggested.

Amarantus receives U.S. patent titled, ‘Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof’

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

USPTO issues patent to Lixte’s lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.